Table 3 Summary of the cost and outcome results in base-case analysis
Strategy | Cost($) | Progression free LYs | Overall LYs | QALYs | Incremental cost per QALY* |
|---|---|---|---|---|---|
1 year (scenario 1) | |||||
 Control | 2,981.3 | 0.35 | 0.51 | 0.30 |  |
 Gefitinib without GPAP | 13,775.3 | 0.56 | 0.67 | 0.42 | 92,968.5 |
 Gefitinib with GPAP | 8,980.4 | 0.56 | 0.67 | 0.42 | 51,669.9 |
2 year (scenario 2) | |||||
 Control | 4,545.6 | 0.36 | 0.57 | 0.33 |  |
 Gefitinib without GPAP | 22,063.0 | 0.81 | 0.97 | 0.60 | 65,514.8 |
 Gefitinib with GPAP | 10,660.6 | 0.81 | 0.97 | 0.60 | 22,870.0 |
5 year (scenario3) | |||||
 Control | 4,913.2 | 0.36 | 0.57 | 0.33 |  |
 Gefitinib without GPAP | 29,705.8 | 1.06 | 1.26 | 0.76 | 57,788.9 |
 Gefitinib with GPAP | 11,884.7 | 1.06 | 1.26 | 0.76 | 16,249.9 |
10 year | |||||
 Control | 4,917.0 | 0.36 | 0.57 | 0.33 |  |
 Gefitinib without GPAP | 31,066.9 | 1.11 | 1.31 | 0.79 | 57,066.4 |
 Gefitinib with GPAP | 12,095.2 | 1.11 | 1.31 | 0.79 | 15,664.8 |